1. Home
  2. ARDC vs VNDA Comparison

ARDC vs VNDA Comparison

Compare ARDC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ARDC

Ares Dynamic Credit Allocation Fund Inc.

HOLD

Current Price

$12.46

Market Cap

306.0M

Sector

Finance

ML Signal

HOLD

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

N/A

Current Price

$5.04

Market Cap

361.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ARDC
VNDA
Founded
N/A
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
306.0M
361.4M
IPO Year
2011
2005

Fundamental Metrics

Financial Performance
Metric
ARDC
VNDA
Price
$12.46
$5.04
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.90
AVG Volume (30 Days)
122.2K
988.6K
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$216,105,000.00
Revenue This Year
N/A
$21.35
Revenue Next Year
N/A
$37.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.72
52 Week Low
$11.60
$4.27
52 Week High
$15.03
$9.91

Technical Indicators

Market Signals
Indicator
ARDC
VNDA
Relative Strength Index (RSI) 45.68 39.80
Support Level $12.32 $4.94
Resistance Level $12.62 $5.44
Average True Range (ATR) 0.13 0.27
MACD 0.01 0.02
Stochastic Oscillator 50.00 60.52

Price Performance

Historical Comparison
ARDC
VNDA

About ARDC Ares Dynamic Credit Allocation Fund Inc.

Ares Dynamic Credit Allocation Fund Inc is a closed-end, diversified, management investment company. The Fund's investment objective is to seek an attractive risk adjusted level of total return, through current income and, secondarily, through capital appreciation. The Fund invests in a broad, dynamically managed portfolio of (i) senior secured loans, (ii) corporate bonds, (iii) other fixed-income instruments, and (iv) securities issued by entities commonly referred to as collateralized loan obligations and other asset-backed securities.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: